Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel Free TRVN Stock Alerts

Trevena (TRVN) Competitors

Trevena logo
$0.0010 0.00 (0.00%)
As of 08/31/2026
Compare

TRVN vs. CMRA, EVLO, EFTR, STAB, and SXTPW

Should you buy Trevena stock or one of its competitors? Trevena's main competitors and comparable companies include Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), eFFECTOR Therapeutics (EFTR), Statera Biopharma (STAB), and 60 Degrees Pharmaceuticals (SXTPW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevena compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

13.6% of Trevena shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Trevena$443K0.00-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Trevena N/A N/A -119.55%

Comera Life Sciences has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Trevena has a beta of -0.44, meaning that its share price is 144% less volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Trevena Neutral

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Trevena compare to Evelo Biosciences?

Trevena (NASDAQ:TRVN) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Trevena has higher revenue and earnings than Evelo Biosciences. Trevena is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

13.6% of Trevena shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevena has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

In the previous week, Evelo Biosciences had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Evelo Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Evelo Biosciences N/A N/A N/A

Summary

Trevena beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Trevena compare to eFFECTOR Therapeutics?

Trevena (NASDAQ:TRVN) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
eFFECTOR Therapeutics N/A N/A N/A

13.6% of Trevena shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Trevena has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

eFFECTOR Therapeutics has lower revenue, but higher earnings than Trevena. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
eFFECTOR Therapeutics Neutral

Summary

eFFECTOR Therapeutics beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Trevena compare to Statera Biopharma?

Trevena (NASDAQ:TRVN) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Statera Biopharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Statera BiopharmaN/AN/AN/AN/AN/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Statera Biopharma Neutral

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 5.5% of Statera Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Trevena has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Statera Biopharma N/A N/A N/A

Summary

Trevena and Statera Biopharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Trevena compare to 60 Degrees Pharmaceuticals?

Trevena (NASDAQ:TRVN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

In the previous week, 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Trevena's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Trevena Neutral
60 Degrees Pharmaceuticals Very Positive

60 Degrees Pharmaceuticals has higher revenue and earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
60 Degrees Pharmaceuticals N/A N/A N/A

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Trevena on 3 of the 5 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

Export
MetricTrevenaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.06B$7.15B$12.83B
Dividend YieldN/A2.60%2.53%11.78%
P/E Ratio0.00784.69271.5924.97
Price / Sales0.00758.91623.5490.61
Price / CashN/A92.7077.2052.85
Price / Book0.0011.9212.986.03
Net Income-$40.29M$2.82B$3.47B$348.89M
7 Day PerformanceN/A1.69%-1.00%-2.29%
1 Month PerformanceN/A4.73%7.13%2.94%
1 Year PerformanceN/A8.51%23.88%14.08%

Trevena Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
N/A$0.00
flat		N/A-99.6%$1K$443KN/A40
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+300.0%$1KN/AN/A10
STAB
Statera Biopharma
N/A$0.00
flat		N/A+0.0%$1KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel